In recent years, macromolecular monoclonal antibodies, a novel class of targeted drugs represented by T-DXd, have emerged as a prominent area of research, ushering in the era of ADC drug therapy and offering expanded treatment options for advanced breast cancer patients who have progressed following CDK4/6 inhibitor treatment. Here, CDK4 is linked to breast cancer.